Literature DB >> 22863690

Long-term follow-up of contacts exposed to multidrug-resistant tuberculosis in Victoria, Australia, 1995-2010.

J T Denholm1, D E Leslie, G A Jenkin, J Darby, P D R Johnson, S M Graham, G V Brown, A Sievers, M Globan, L K Brown, E S McBryde.   

Abstract

SETTING: The effectiveness of public health strategies following exposure to multidrug-resistant tuberculosis (MDR-TB) is not clear.
OBJECTIVE: To perform long-term follow-up of MDR-TB contacts and review individual outcomes and management approaches.
DESIGN: Retrospective review of MDR-TB contacts identified by the Victorian Department of Health from 1995 to 2010. Health records, including personal medical and pharmacy records and statewide clinical and laboratory TB databases, were searched to identify management strategies and individual outcomes.
RESULTS: A total of 570 contacts of 47 MDR-TB cases were identified, with a total follow-up period of 3093 person-years of observation (PYO) since exposure. Of 570 contacts, 49 (8.6%) were considered likely to have been infected with Mycobacterium tuberculosis from index cases, and 11/49 (22.5%) of these were prescribed preventive therapy tailored to isolate susceptibility. No MDR-TB cases occurred in those receiving preventive treatment, while two cases were observed in those not treated (incidence 2878/100 000 PYO during the first 2 years post exposure).
CONCLUSIONS: The risk of MDR-TB transmission to close contacts in this low-prevalence setting highlights the potential for public health strategies involving preventive treatment.

Entities:  

Mesh:

Year:  2012        PMID: 22863690     DOI: 10.5588/ijtld.12.0092

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  12 in total

1.  Isoniazid Preventive Therapy in Contacts of Multidrug-Resistant Tuberculosis.

Authors:  Chuan-Chin Huang; Mercedes C Becerra; Roger Calderon; Carmen Contreras; Jerome Galea; Louis Grandjean; Leonid Lecca; Rosa Yataco; Zibiao Zhang; Megan Murray
Journal:  Am J Respir Crit Care Med       Date:  2020-10-15       Impact factor: 21.405

2.  Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.

Authors:  Payam Nahid; Sundari R Mase; Giovanni Battista Migliori; Giovanni Sotgiu; Graham H Bothamley; Jan L Brozek; Adithya Cattamanchi; J Peter Cegielski; Lisa Chen; Charles L Daley; Tracy L Dalton; Raquel Duarte; Federica Fregonese; C Robert Horsburgh; Faiz Ahmad Khan; Fayez Kheir; Zhiyi Lan; Alfred Lardizabal; Michael Lauzardo; Joan M Mangan; Suzanne M Marks; Lindsay McKenna; Dick Menzies; Carole D Mitnick; Diana M Nilsen; Farah Parvez; Charles A Peloquin; Ann Raftery; H Simon Schaaf; Neha S Shah; Jeffrey R Starke; John W Wilson; Jonathan M Wortham; Terence Chorba; Barbara Seaworth
Journal:  Am J Respir Crit Care Med       Date:  2019-11-15       Impact factor: 21.405

3.  Willingness to Take Multidrug-resistant Tuberculosis (MDR-TB) Preventive Therapy Among Adult and Adolescent Household Contacts of MDR-TB Index Cases: An International Multisite Cross-sectional Study.

Authors:  Nishi Suryavanshi; Matthew Murrill; Amita Gupta; Michael Hughes; Anneke Hesseling; Soyeon Kim; Linda Naini; Lynne Jones; Betsy Smith; Nikhil Gupte; Rodney Dawson; Vidya Mave; Sushant Meshram; Alberto Mendoza-Ticona; Jorge Sanchez; Nagalingeswaran Kumarasamy; Kyla Comins; Francesca Conradie; Justin Shenje; Sandy Nerette Fontain; Anthony Garcia-Prats; Aida Asmelash; Supalert Nedsuwan; Lerato Mohapi; Umesh Lalloo; Ana Cristina Garcia Ferreira; Elisha Okeyo; Susan Swindells; Gavin Churchyard; N Sarita Shah
Journal:  Clin Infect Dis       Date:  2020-01-16       Impact factor: 9.079

Review 4.  Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis.

Authors:  Suzanne M Marks; Sundari R Mase; Sapna Bamrah Morris
Journal:  Clin Infect Dis       Date:  2017-06-15       Impact factor: 9.079

5.  Risk Factors for Adverse Events in Household Contacts Prescribed Preventive Treatment for Drug-resistant Tuberculosis Exposure.

Authors:  Amyn A Malik; Mercedes C Becerra; Timothy L Lash; Lisa M Cranmer; Saad B Omer; Junaid Fuad; Sara Siddiqui; Farhana Amanullah; Maria Jaswal; Naseem Salahuddin; Salmaan Keshavjee; Hamidah Hussain; Neel R Gandhi
Journal:  Clin Infect Dis       Date:  2021-05-18       Impact factor: 20.999

6.  Cost-effectiveness of adding bedaquiline to drug regimens for the treatment of multidrug-resistant tuberculosis in the UK.

Authors:  Lara J Wolfson; Anna Walker; Robert Hettle; Xiaoyan Lu; Chrispin Kambili; Andrew Murungi; Gerhart Knerer
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

7.  The Use of Fluoroquinolones for Tuberculosis in Victoria between 2011 and 2016.

Authors:  Hugh Murray; Ee Laine Tay; Sarah Dinh; Helen Matthews; Alan Street; Justin T Denholm
Journal:  Tuberc Res Treat       Date:  2018-07-02

8.  Prevention of Multidrug-Resistant Tuberculosis in Close Contacts. Back to the Future?

Authors:  Neil W Schluger
Journal:  Am J Respir Crit Care Med       Date:  2020-10-15       Impact factor: 21.405

Review 9.  Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.

Authors:  Haileyesus Getahun; Alberto Matteelli; Ibrahim Abubakar; Mohamed Abdel Aziz; Annabel Baddeley; Draurio Barreira; Saskia Den Boon; Susana Marta Borroto Gutierrez; Judith Bruchfeld; Erlina Burhan; Solange Cavalcante; Rolando Cedillos; Richard Chaisson; Cynthia Bin-Eng Chee; Lucy Chesire; Elizabeth Corbett; Masoud Dara; Justin Denholm; Gerard de Vries; Dennis Falzon; Nathan Ford; Margaret Gale-Rowe; Chris Gilpin; Enrico Girardi; Un-Yeong Go; Darshini Govindasamy; Alison D Grant; Malgorzata Grzemska; Ross Harris; C Robert Horsburgh; Asker Ismayilov; Ernesto Jaramillo; Sandra Kik; Katharina Kranzer; Christian Lienhardt; Philip LoBue; Knut Lönnroth; Guy Marks; Dick Menzies; Giovanni Battista Migliori; Davide Mosca; Ya Diul Mukadi; Alwyn Mwinga; Lisa Nelson; Nobuyuki Nishikiori; Anouk Oordt-Speets; Molebogeng Xheedha Rangaka; Andreas Reis; Lisa Rotz; Andreas Sandgren; Monica Sañé Schepisi; Holger J Schünemann; Surender Kumar Sharma; Giovanni Sotgiu; Helen R Stagg; Timothy R Sterling; Tamara Tayeb; Mukund Uplekar; Marieke J van der Werf; Wim Vandevelde; Femke van Kessel; Anna van't Hoog; Jay K Varma; Natalia Vezhnina; Constantia Voniatis; Marije Vonk Noordegraaf-Schouten; Diana Weil; Karin Weyer; Robert John Wilkinson; Takashi Yoshiyama; Jean Pierre Zellweger; Mario Raviglione
Journal:  Eur Respir J       Date:  2015-09-24       Impact factor: 16.671

10.  Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement.

Authors:  Christoph Lange; Ibrahim Abubakar; Jan-Willem C Alffenaar; Graham Bothamley; Jose A Caminero; Anna Cristina C Carvalho; Kwok-Chiu Chang; Luigi Codecasa; Ana Correia; Valeriu Crudu; Peter Davies; Martin Dedicoat; Francis Drobniewski; Raquel Duarte; Cordula Ehlers; Connie Erkens; Delia Goletti; Gunar Günther; Elmira Ibraim; Beate Kampmann; Liga Kuksa; Wiel de Lange; Frank van Leth; Jan van Lunzen; Alberto Matteelli; Dick Menzies; Ignacio Monedero; Elvira Richter; Sabine Rüsch-Gerdes; Andreas Sandgren; Anna Scardigli; Alena Skrahina; Enrico Tortoli; Grigory Volchenkov; Dirk Wagner; Marieke J van der Werf; Bhanu Williams; Wing-Wai Yew; Jean-Pierre Zellweger; Daniela Maria Cirillo
Journal:  Eur Respir J       Date:  2014-03-23       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.